Citigroup’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Citigroup’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,500	Closed	-$12K	–	7765
2020 Q1	$12K	Sell	1,500 -7,200	-83%	-$108K	﹤0.01%	6987
2019 Q4	$180K	Sell	8,700 -18,200	-68%	-$307K	﹤0.01%	5274
2019 Q3	$369K	Buy	26,900 +8,900	+49%	+$106K	﹤0.01%	4634
2019 Q2	$221K	Buy	18,000 +8,000	+80%	+$92.3K	﹤0.01%	5173
2019 Q1	$125K	Hold	10,000	–	–	﹤0.01%	5543
2018 Q4	$113K	Sell	10,000 -900	-8%	-$14.1K	﹤0.01%	5551
2018 Q3	$204K	Buy	10,900 +2,700	+33%	+$62K	﹤0.01%	5236
2018 Q2	$212K	Buy	8,200 +2,900	+55%	+$75.3K	﹤0.01%	5008
2018 Q1	$119K	Buy	+5,300	New	+$129K	﹤0.01%	5451

Citigroup's FLXN Position: Q4 2021 in Review

Citigroup sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 23,901 shares — an estimated $146K sold.

Citigroup first reported a position in FLXN in Q1 2014 and held it in 31 quarters. The position peaked at $3.19M in Q4 2017. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Citigroup reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Citigroup sold 23,901 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $146K.
Citigroup first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 31 quarters.
Citigroup's Flexion Therapeutics, Inc. position peaked at $3.19M in Q4 2017.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.